» Articles » PMID: 26020252

The Use of Nanotrap Particles in the Enhanced Detection of Rift Valley Fever Virus Nucleoprotein

Overview
Journal PLoS One
Date 2015 May 29
PMID 26020252
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Rift Valley fever virus (RVFV) is a highly pathogenic arthropod-borne virus that has a detrimental effect on both livestock and human populations. While there are several diagnostic methodologies available for RVFV detection, many are not sensitive enough to diagnose early infections. Furthermore, detection may be hindered by high abundant proteins such as albumin. Previous findings have shown that Nanotrap particles can be used to significantly enhance detection of various small analytes of low abundance. We have expanded upon this repertoire to show that this simple and efficient sample preparation technology can drastically improve the detection of the RVFV nucleoprotein (NP), the most abundant and widely used viral protein for RVFV diagnostics.

Results: After screening multiple Nanotrap particle architectures, we found that one particle, NT45, was optimal for RVFV NP capture, as demonstrated by western blotting. NT45 significantly enhanced detection of the NP at levels undetectable without the technology. Importantly, we demonstrated that Nanotrap particles are capable of concentrating NP in a number of matrices, including infected cell lysates, viral supernatants, and animal sera. Specifically, NT45 enhanced detection of NP at various viral titers, multiplicity of infections, and time points. Our most dramatic results were observed in spiked serum samples, where high abundance serum proteins hindered detection of NP without Nanotrap particles. Nanotrap particles allowed for sample cleanup and subsequent detection of RVFV NP. Finally, we demonstrated that incubation of our samples with Nanotrap particles protects the NP from degradation over extended periods of time (up to 120 hours) and at elevated temperatures (at 37ºC).

Conclusion: This study demonstrates that Nanotrap particles are capable of drastically lowering the limit of detection for RVFV NP by capturing, concentrating, and preserving RVFV NP in clinically relevant matrices. These studies can be extended to a wide range of pathogens and their analytes of diagnostic interest.

Citing Articles

On-site airborne pathogen detection for infection risk mitigation.

Qiu G, Zhang X, deMello A, Yao M, Cao J, Wang J Chem Soc Rev. 2023; 52(24):8531-8579.

PMID: 37882143 PMC: 10712221. DOI: 10.1039/d3cs00417a.


Comparative analysis of Adsorption-Extraction (AE) and Nanotrap® Magnetic Virus Particles (NMVP) workflows for the recovery of endogenous enveloped and non-enveloped viruses in wastewater.

Ahmed W, Bivins A, Korajkic A, Metcalfe S, Smith W, Simpson S Sci Total Environ. 2022; 859(Pt 1):160072.

PMID: 36356768 PMC: 10823496. DOI: 10.1016/j.scitotenv.2022.160072.


Use of magnetic nanotrap particles in capturing Yersinia pestis virulence factors, nucleic acids and bacteria.

Ii A, Lin S, Lepene B, Zhou W, Kehn-Hall K, van Hoek M J Nanobiotechnology. 2021; 19(1):186.

PMID: 34154629 PMC: 8215484. DOI: 10.1186/s12951-021-00859-8.


Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus.

Polyakov D, Sinitsyna E, Grudinina N, Antipchik M, Sakhabeev R, Korzhikov-Vlakh V Pharmaceutics. 2021; 13(5).

PMID: 34067169 PMC: 8151308. DOI: 10.3390/pharmaceutics13050672.


Hydrogel particles improve detection of SARS-CoV-2 RNA from multiple sample types.

Barclay R, Akhrymuk I, Patnaik A, Callahan V, Lehman C, Andersen P Sci Rep. 2020; 10(1):22425.

PMID: 33380736 PMC: 7773739. DOI: 10.1038/s41598-020-78771-8.


References
1.
Paul D, Kumar A, Gajbhiye A, Santra M, Srikanth R . Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int. 2013; 2013:783131. PMC: 3613068. DOI: 10.1155/2013/783131. View

2.
Luchini A, Fredolini C, Espina B, Meani F, Reeder A, Rucker S . Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. Curr Mol Med. 2010; 10(2):133-41. PMC: 2873152. DOI: 10.2174/156652410790963268. View

3.
Baer A, Kehn-Hall K . Viral concentration determination through plaque assays: using traditional and novel overlay systems. J Vis Exp. 2014; (93):e52065. PMC: 4255882. DOI: 10.3791/52065. View

4.
Madani T, Al-Mazrou Y, Al-Jeffri M, Mishkhas A, Al-Rabeah A, Turkistani A . Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis. 2003; 37(8):1084-92. DOI: 10.1086/378747. View

5.
Tuck M, Chan D, Chia D, Godwin A, Grizzle W, Krueger K . Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2008; 8(1):113-7. PMC: 2655764. DOI: 10.1021/pr800545q. View